BiotechTube

rhuFlt3L/CDX-301 + Poly-ICLC

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Low-Grade B-cell Lymphoma

Conditions

Low-Grade B-cell Lymphoma

Trial Timeline

Jan 3, 2014 → Nov 20, 2020

NCT ID
NCT01976585

About rhuFlt3L/CDX-301 + Poly-ICLC

rhuFlt3L/CDX-301 + Poly-ICLC is a phase 1/2 stage product being developed by Celldex Therapeutics for Low-Grade B-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01976585. Target conditions include Low-Grade B-cell Lymphoma.

What happened to similar drugs?

0 of 3 similar drugs in Low-Grade B-cell Lymphoma were approved

Approved (0) Terminated (1) Active (2)
❌MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3
🔄rituximabBiogenPhase 3
🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01976585Phase 1/2Completed

Competing Products

13 competing products in Low-Grade B-cell Lymphoma

See all competitors
ProductCompanyStageHype Score
Rabeprazole SodiumEisaiPre-clinical
26
Binimetinib 15 MGOno PharmaceuticalPhase 2
42
EverolimusNovartisPhase 2
35
MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3
32
Fludarabine Phosphate (Fludara) + RituximabSanofiPhase 2
35
rituximabBiogenPhase 3
37
TovorafenibIpsenPhase 1
33
TovorafenibDay One BiopharmaceuticalsPhase 2
36
Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3
41
DAY101Day One BiopharmaceuticalsPhase 1
23
TovorafenibDay One BiopharmaceuticalsPre-clinical
20
TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBDTyra BiosciencesPhase 2
36
combined therapy with rh-ES and CVBrain BiotechPhase 2
25